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INTRODUCTION
Colorectal cancer is the fourth most common malignancy
in Korea, with 10,000 new cases and 5,000 deaths each year,
and its incidence is increasing (1). About 20% of colorectal
cancer patients are diagnosed in the metastatic stage and,
even if curative surgical treatment is performed, about 40%
of patients will experience local or distant recurrences (2).
Until the early 1990s, 5-fluorouracil (5-FU) was consid-
ered the only effective chemotherapeutic drug for colorectal
cancer. In the past decade, however, the introduction of the
topoisomerase-I inhibitor irinotecan and the third-genera-
tion platinum derivative oxaliplatin has increased the medi-
an survival among patients with advanced colorectal cancer
(3, 4). Currently, irinotecan and oxaliplatin are used in com-
bination with 5-FU and leucovorin as first and second-line
treatment for advanced colorectal cancer. 
The epidermal growth factor receptor (EGFR) is a mem-
ber of the HER family of receptors, which are involved in
signaling pathways affecting cell growth, differentiation,
proliferation and programmed cell death. The receptors are
overexpressed in many solid tumors, and the overexpression
of EGFR has been associated with poor prognosis in patients
with colorectal cancer (5). Clinically, this receptor can be
inhibited by the monoclonal antibody cetuximab or by the
tyrosine kinase inhibitors gefitinib and erlotinib. 
Cetuximab is a monoclonal antibody directed against the
extracellular binding domain of the EGFR. In advanced col-
orectal cancer patients refractory to irinotecan alone or to com-
bination chemotherapy including irinotecan, the combina-
tion of cetuximab and irinotecan showed improved response
rates and an increased median time to disease progression com-
pared with cetuximab alone (6).
We therefore assessed the efficacy and safety of a combina-
tion of weekly cetuximab and biweekly irinotecan and infu-
sional 5-FU/leucovorin (FOLFIRI) and the association bet-
ween the EGFR status and response. 
MATERIALS AND METHODS
Patients and EGFR staining
From September 2004 to February 2006, patients who ful-
filled the following eligibility criteria were enrolled in this
phase II study. The eligibility criteria for this study were 1)
histologically confirmed metastatic colorectal adenocarcino-
ma without central nervous system (CNS) metastasis, 2) prior
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A Phase II Study of Cetuximab (Erbitux
�) plus FOLFIRI for Irinotecan
and Oxaliplatin-refractory Metastatic Colorectal Cancer
We have evaluated the efficacy and safety of cetuximab plus FOLFIRI for irinotecan
and oxaliplatin-refractory colorectal cancers. From September 2004 to February
2006, 31 patients with metastatic colorectal cancer were treated with cetuximab
(400 mg/m
2 intravenously [IV] over 2 hr on day 1 followed by weekly 1-hr infusions
of 250 mg/m
2) plus bi-weekly FOLFIRI (irinotecan 150 mg/m
2 IV over 90 min, and
leucovorin 100 mg/m
2 IV over 2 hr, followed by 5-FU 400 mg/m
2 IV bolus on day 1,
and followed by 5-FU 2,400 mg/m
2 by continuous IV over 46 hrs). Patients receiv-
ed a median of four cycles (range: 1-23). Eight (25.8%) patients had confirmed
partial responses and 10 (32.2%) had stable disease. After a median follow-up of
13.2 months for surviving patients, the median time to progression was 2.9 months,
the median duration of response was 5.4 months, and the median overall survival
was 10.9 months. Skin toxicity was observed in 25 patients (80.4%) including grade
3 in 6 patients (19.4%). Other common non-hematologic toxicities of all grades
were mucositis (32.3%), asthenia (22.6%), diarrhea (12.9%), and paronychial crack-
ing (12.9%). The combination of cetuximab with FOLFIRI was effective and tolera-
ble in colorectal cancer patients heavily pretreated with a number of chemothera-
py regimens.
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palliative chemotherapy with fluoropyrimidine (5-FU, capeci-
tabine), irinotecan and oxaliplatin, 3) documented progres-
sion of radiological evidence during chemotherapy with these
agents, 4) at least one unidimensionally measurable lesion
according to Response Evaluation Criteria In Solid Tumors
(RECIST), 5) performance score (PS) of 0-2 according to the
Eastern Cooperative Oncology Group (ECOG) scale, and 6)
adequate bone marrow function (hemoglobin ≥10.0 g/dL;
leukocyte ≥4,000 cells/ L; platelet ≥100,000 cells/ L),
adequate liver function (serum bilirubin level ≤2.0 mg/dL;
serum transaminase level ≤3 times the upper limit of the
normal range) and renal function (serum creatinine level ≤
1.4 mg/dL).
Immunohistochemical evidence of the EGFR expression
was measured semiquantitatively (>0 on a scale of 0, 1+,
2+, or 3+) in a single reference laboratory. These measure-
ments were performed at the Central Laboratory (Prince of
Wales Hospital, Sha Tin, Hong Kong) and graded using a
commercially available kit (EGFRpharmDx; Dako Corpo-
ration, Carpinteria, CA, U.S.A.) on paraffin-embedded tumor
specimens according to the manufacturer’s instructions.
Study design and treatment 
This study was designed as a phase II trial. All patients pro-
vided written informed consent, and the institutional review
boards (IRB) of Asan Medical Center approved the study pro-
tocol. In this study, the estimation of the sample size was as
below. The Simon two-stage phase II design provided 90%
power and a 0.05 level of significance overall to distinguish
between the null and alternative hypotheses, where the null
hypothesis (H0) is that the true overall response rate is <5%,
and the alternative hypothesis (H1) is that the true overall
response rate is >25%. The trial would be terminated at
nine patients if zero patients have responded or be studied
at 30 patients if the trial goes on to the second stage.
Cetuximab (400 mg/m2) was administered intravenously
(IV) on day 1 over 2 hr, followed by weekly 1-hr infusions of
250 mg/m2. A histamine-receptor antagonist was given as
premedication before at least the first infusion. FOLFIRI con-
sisted of irinotecan (150 mg/m2) IV over 90 min, and leu-
covorin (100 mg/m2) IV over 2 hr, immediately followed by
5-FU (400 mg/m2) IV bolus on day 1, and followed by 5-FU
(2,400 mg/m2) by continuous IV over 46 hr. Patients were
scheduled to receive biweekly FOLFIRI with weekly cetux-
imab. If a patient experiences grade 3 of skin toxicity, cetux-
imab therapy may be deferred for up to two consecutive
weeks without changing the dose level. If the toxicity resolves
to grade 2 or less by the following treatment period, the
treatment may resume. With the second or third occurrences
of grade 3 skin toxicity, cetuximab therapy may be deferred
again for up to two consecutive weeks with concomitant
dose reductions to 200 or 150 mg/m2, respectively. Patients
had to discontinue cetuximab if more than two consecutive
infusions were withheld or a fourth occurrence of grade 3
skin toxicity occurred despite an appropriate dose reduction.
Cetuximab was not withheld for FOLFIRI-related toxicity.
The dose of FOLFIRI was reduced by 25% if grade 3 or hi-
gher non-hematologic toxicities (such as stomatitis or diar-
rhea) were observed during the treatment period or grade 2
hematologic toxicity (leukocyte 3,000-4,000 cells/ L or pla-
telet 75,000-100,000 cells/ L) was observed immediately
prior to administration of the FOLFIRI regimen. If there
was grade 3 or higher leukopenia or thrombocytopenia, the
FOLFIRI regimen was delayed until recovery.
Evaluation and statistical analysis 
The primary end point was the rate of confirmed radiologic
tumor response, according to RECIST after every three cycles
of chemotherapy. Radiologic evaluation consisted of chest
radiography and abdominopelvis CT scans. Secondary end-
points were the evaluation of time to disease progression
(TTP), time to treatment failure (TTF), overall survival (OS)
and the safety profile in the intent-to treat analysis. TTP was
defined as the time from treatment start to either progres-
sion of cancer or death from any cause. TTF was defined as
the time from treatment start to either discontinuation of
treatment or death from any cause. OS was defined as the
time from treatment start to death from any cause. Survival
curves were estimated using the Kaplan-Meier method. Safe-
ty was assessed in terms of toxicity and evaluated as grades
1 to 4 based on the Common Terminology Criteria for Adverse
Events (CTCAE), version 3.0. 
To assess the relative significance of potential prognostic
factors, we performed univariate and multivariate analyses
using the log-rank test and the Cox proportional hazards
models, respectively. A p value <0.05 was considered statis-
tically significant, and all analyses were performed using SPSS
12.0 for Windows. 
RESULTS
Patient characteristics
From September 2004 to February 2006, a total of 31 pa-
tients met the eligibility criteria; their baseline characteris-
tics are listed in Table 1. Of these patients, 25 (80.6%) under-
went surgical resection of their primary tumor and 14 (45.2
%) had received more than 2 regimens of palliative chemo-
therapy. The median number of cycles of cetuximab plus
FOLFIRI administered was four (range: 1-23).
Response 
The overall response rate (i.e. complete responses [CR]+
partial responses [PR] rates) was 25.8% (95% CI, 10.4-41.2S100 D.H. Koo, J.-L. Lee, T.W. Kim, et al.
%). The median duration of response was 5.4 months (95%
CI, 2.1-8.7 months). The disease control rate (i.e. CR+PR+
stable disease [SD]) was 58.0% patients (95% CI, 40.6-75.4
%) (Table 2).
Survival outcome
Of the 31 patients, 11 (33.3%) remained alive at a median
follow-up of 13.2 months. The median TTP was 2.9 months
(95% CI, 1.4-4.4 months) and the median TTF was 2.1 mon-
ths. Treatment failure was caused by disease progression (87.0
%), financial burden (6.5%), and inability to tolerate treat-
ment (6.5%). The median OS was 10.9 months (95% CI,
3.8-18.0 months), and the 1-yr OS rate was 47.6% (Fig. 1). 
EGFR expression and response
Among the 15 patients whose tumor tissue was available
to test for EGFR expression, 13 (86.7%) had tumor cell ex-
pression ranging from 1+ to 3+. The presence or degree of
EGFR expression did not correlate significantly with clini-
cal response rate (p=0.32) (Table 3).
Safety and toxicity
The 31 patients received 212 cycles of chemotherapy. Safe-
ty evaluation showed that the most common hematologic
toxicity was neutropenia (54.8%), followed by thrombocy-
topenia (3.2%). Grade 3 or higher neutropenia developed in
11 (35.5%) patients, but there were no incidents of neutro-
penic fever or treatment-related mortality. An acne-like skin
rash was observed in 25 (80.6%) patients, with grade 3 tox-
icity in 6 (19.4%). After the sixth administration of cetux-
imab (median two, range 1-6), almost all patients developed
a skin rash. Other common non-hematologic toxicities were
mucositis (32.3%), asthenia (22.6%), diarrhea (12.9%), and
paronychial cracking (12.9%) (Table 4). 
Characteristics n (%)
Median age, yr (range)  61 (32-76)
Gender
Male 20 (64.5)
Female 11 (35.5)
Performance status (ECOG) 
0-1 21 (67.7)
2 10 (32.3)
Histology 
W/D, M/D 22 (71.0)
P/D, Mucinous 7 (22.6)
Not available 2 (6.5)
No. of metastatic sites
1 11 (35.5)
≥2 21 (64.5)
Sites of metastasis
Liver 23  (74.2)
Peritoneal 11 (35.5)
Distant lymph nodes 11 (35.5)
Lung 11 (35.5)
Previous resection of primary tumor
Yes 25 (80.6)
No 6 (19.4)
No. of previous palliative chemotherapy treatment lines 
2 17 (54.8)
≥3 14 (45.2)
Table 1. Baseline demographic and clinical characteristics of
patients (n=31)
Response n (%)
Complete response 0 (0.0)
Partial response 8 (25.8)
Stable disease 10 (32.3)
Disease progression 11 (35.5)
Not evaluable 2 (6.5)
Table 2. Response to treatment 
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Fig. 1. Survival curves; (A) Time to progression and (B) Overall survival.
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There was a correlation between the presence and severity
of the acne-like skin toxicity and response rate and survival.
As shown in Table 5, there were superior response rates (p=
0.02) and survival rates (p<0.01) with higher grades of skin
toxicity. 
Prognostic factors
Univariate analysis of the relationship between survival
outcome and clinicopathologic factors showed that the absence
of skin rash was significantly associated with TTP, whereas
poor performance status and the absence of skin rash were
significant negative prognostic factors for OS. Multivariate
analysis also identified the absence of skin rash as an inde-
Toxicities All grades n (%) Grade ≥3 n (%)
Allergic reaction 1 (3.2) -
Acne-like rash 25 (80.4) 6 (19.4)
Asthenia 7 (22.6) 2 (6.5)
Diarrhea 4 (12.9) 1 (3.2)
Dyspnea 1 (3.2) -
Fever 3 (9.7) -
Mucositis 10 (32.3) 2 (6.5)
Nausea/vomiting 3 (9.7) -
Neuropathy 3 (9.7) -
Paronychial cracking 4 (12.9) -
Table 4. Non-hematologic toxicities based on CTCAE version
3.0 (n=31)
Skin toxicity
Patients 
(n)
Response
rate (%)
Disease
control rate
(%)
Median time to
progression
(months)
Grade 0 6 0 (0) 0 (0) 1.8 mo
Grade 1-2 19 6 (31.6) 12 (63.2) 3.0 mo
Grade 3 6 2 (33.3) 6 (100.0) 6.3 mo
Table 5. Response rate and time to progression in relation to
skin toxicity
EGFR expression n (%) Response rate
- 2 (13.3) 1 (50.0%)
1+ 2 (13.3) 2 (100.0%)
2+ 6 (40.0) 1 (16.7%)
3+ 5 (33.4) 0 (0.0%)
Table 3. EGFR expression according to staining intensity (n=15)
Factors (n)
Univariate
TTP
Median
(months)
p
OS
Median
(months)
p
Multivariate
TTP
HR 
(95% CI)
p
OS
HR 
(95% CI)
p
Age
<60 yr (15) 4.4  0.48 13.0  0.15 1.20 (0.26-2.58) 0.64 2.25 (0.79-6.42) 0.13
≥61 yr (16) 2.0  4.5 
Gender
Female (11) 2.0  0.93 8.1 0.92 0.96 (0.43-2.16) 0.93 0.80 (0.21-3.03) 0.74
Male (20) 3.0 10.9
ECOG (PS)
1 (21) 5.1 0.06 16.2 <0.01 2.00 (0.89-4.52) 0.09 8.67 (2.85-26.43) <0.01
2 (10) 1.6 2.9
Skin rash
Absent (6) 1.6 0.01 2.8 <0.01 3.27 (1.13-9.45) 0.03 18.10 (3.57-91.67) <0.01
Present (25) 3.6 13.0
EGFR status 
Absent (2) 2.0 0.21 12.7 0.94 ----
Expressed (13) 2.2 8.1
Histology 
W/D, M/D (22) 2.9 0.70 8.1 0.95 ----
P/D, mucinous (7) 2.7 13.0
No. of metastases 
1 (11) 5.4 0.10 13.0 0.13 ----
≥2 (20) 2.2 6.0
No. of previous chemotherapy lines
<2 (17) 2.9  0.52 16.2 0.07 ----
≥3 (14) 2.0 8.1
Table 6. Univariate and multivariate analysis of clinicopathologic factors potentially associated with survival outcome 
TTP, time to progression; OS, overall survival; HR, hazard ratio; CI, confidence interval; mo, months; ECOG, Eastern Cooperative Oncology Group;
EGFR, epidermal growth factor receptor; W/D, well differentiated; M/D, moderately differentiated; P/D, poorly differentiated.
CTCAE, Common Terminology Criteria for Adverse Events.
EGFR, epidermal growth factor receptor.S102 D.H. Koo, J.-L. Lee, T.W. Kim, et al.
pendent factor indicative of poor prognosis for TTP, and the
poor performance status and the absence of skin rash were
independent prognostic factors negatively affecting the over-
all survival (Table 6). 
DISCUSSION
We have evaluated the efficacy, safety and clinical feasibil-
ity of cetuximab plus FOLFIRI for patients with irinotecan
and oxaliplatin-refractory advanced colorectal cancer. The
EGFR-targeting monoclonal antibody, cetuximab, has been
shown to be effective in patients with irinotecan-refractory
colorectal cancer (6). That study showed that the combina-
tion of cetuximab and irinotecan resulted in greater efficacy
than cetuximab alone, with a higher objective response rate
(22.9% vs. 10.8%), overall disease control rate (55.5% vs.
32.4%), and a prolonged time to progression (4.1 vs. 1.5
months). Our response rate was comparable with the result
of that study. In addition, our results confirm that pretreat-
ment with oxaliplatin did not have a negative impact on the
response to cetuximab plus irinotecan since all our patients
had been previously treated with oxaliplatin.
Although the pivotal studies combined cetuximab with
irinotecan, the current study involves 5-FU and leucovorin
in addition. As cetuximab potentiates the anti-tumor effects
of irinotecan significantly compared with either irinotecan
or cetuximab monotherapy in vivo and in vitro (7), the same
or similar synergistic effect is expected in combination of 5-
FU and cetuximab. In addition, the result of irinotecan plus
5-FU/LV was superior to that of irinotecan monotherapy for
5-FU-refractory colorectal cancer (3). A recent study showed
that the pharmacokinetic properties of cetuximab were unaf-
fected by co-administration of 5-FU in comparison with ad-
ministration of cetuximab as a single agent or cetuximab
plus irinotecan (8). Our study showed comparable side effects
with another study in which salvage FOLFIRI regimen was
given to patients with refractory advanced gastric cancer
except skin toxicity, a typical side effect of EGFR targeted
therapies (9). Therefore, the addition of 5-FU/leucovorin to
irinotecan and cetuximab is considered to be effective and
tolerable to patients who were heavily pretreated with many
chemotherapy regimens. A comparative study to evaluate
the efficacy and safety of the FOLFIRI regimen versus FO-
LFIRI plus cetuximab is underway. 
Acne-like skin toxicity, an adverse event typical of cetux-
imab as well as of other anti-EGFR agents, was associated
with increased response rates and a prolonged median sur-
vival time in patients with colorectal cancer. Furthermore,
in agreement with previous studies we found that higher-
grade skin toxicities were associated with a longer TTP (10,
11). Although the mechanism of correlation between skin
toxicity and tumor response has not been fully clarified, skin
toxicity is currently regarded as a surrogate marker of tumor
response as has been shown by our analysis of prognostic
factors. As in previous studies we could also show that tumor
expression of EGFR did not correlate with objective tumor
responses (6, 12). Thus, the EGFR expression measured by
the current test-kit does not seem to predict the treatment
outcome. Therefore, in clinical practice, no patient should
be included or excluded from cetuximab therapy on the basis
of EGFR test results (13). Factors that can predict antitumor
response or clinical benefit from cetuximab therapy are cur-
rently under investigation (14, 15), both to optimize thera-
peutic indications and to reduce toxicities and costs.
More recently, clinical trials incorporated cetuximab into
first-line (8) or adjuvant (16) treatment settings for metastat-
ic colon cancer and also evaluated the use of cetuximab with
other targeted agents (17, 18), such as bevacizumab, gefi-
tinib and erlotinib. In addition, cetuximab with oxaliplatin-
based chemotherapy (5-FU, leucovorin, oxaliplatin: FOL-
FOX) has been reported to show similar efficacy data com-
pared to cetuximab when it is combined with FOLFIRI (19).
Its effectiveness in colorectal and head-and-neck cancers (20)
has prompted the investigation of cetuximab in the treat-
ment of other solid tumors.
Although patients with advanced cancer have a greater
opportunity to receive these treatments, the high cost of the
treatments can lead to a considerable financial burden. For
example, an eight-week course of the FOLFIRI plus cetux-
imab regimen costs nearly $30,790 in the United States and
about $23,600 in Korea (21). Cost is an important factor
determining which patients with advanced-stage cancer to
receive treatment. In fact, the financial burdens led to treat-
ment discontinuance in 6.5% of our patients and even dis-
couraged patients who wanted to receive cetuximab.
Despite a limitation of the small sample size, we have
shown here that the combination of weekly cetuximab and
biweekly FOLFIRI is effective as third-line treatment in
irinotecan and oxaliplatin-refractory colorectal cancer pati-
ents. This treatment regimen was also safe and tolerable,
but its cost-effectiveness still needs to be evaluated.
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